Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0851184 (thinning)
 11,252 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We measured the thickness of the glomerular basement membrane (GBM) in 48 rheumatoid arthritis (RA) patients with proteinuria and/or hematuria and studied its relationship to clinical features of RA. Ten cases with minor glomerular abnormalities, renal cancer, donor of renal transplantation, were studied as controls. Secondary glomerular diseases and hereditary thin basement membrane disease (TBMD) were excluded. Mean GBM thickness was 289 +/- 74 nm (mean +/- SD) in RA patients, which was significantly thinner than that of control group (342 +/- 38 nm) (p < 0.01). Mean GBM thickness were 276 +/- 72 nm and 336 +/- 68 nm in RA patients with and without gold sodium thiomalate (GST) treatment, respectively (p < 0.05). Mean GBM thickness of RA patients without GST and controls were not different statistically, but RA patients with GST had significantly thinner GBM, compared with controls (p < 0.01). The mean thickness of GBM were also 274 +/- 69 nm and 344 +/- 72 nm in RA patients with and without hematuria, respectively (p < 0.01). According to these results, we suspect that the thinning of GBM in RA patients may be related to GST treatment.
 ...
PMID:An ultrastructural study of glomerular basement membrane in rheumatoid arthritis patients with urinary abnormalities. 755 19

The Philippine Family Planning Program formally re-introduced depomedroxyprogesterone acetate (DMPA) or DepoProvera as a program method last March 22, 1994. DMPA will be added to the choices available to couples who desire to practice responsible parenthood. DMPA is an injectable contraceptive containing synthetic progestin which resembles progesterone. It is a scientifically effective, medically safe and legal contraceptive which is injected every three months. Its effectivity reaches up to 99.7% in the first year of use. A WHO [World Health Organization] study had shown that its effectiveness is comparable to bilateral tubal ligation. DMPA's mechanism of action is the inhibition of ovulation and the thinning of the endometrium. It is a safe contraceptive which the US Drug and Food Authority (USDFA) and our own Bureau of Food and Drug Authority had approved for contraceptive use. WHO studies had shown that DMPA does not lead to increased cancer risk, congenital malformation and infertility. DMPA was initially developed in the 1960s as a treatment for endometrial and renal cancer. Its contraceptive effects then led to its use as a family planning method. Over 9 million women had used DMPA. It is a very safe, reversible and effective family planning method with manageable side effects. These include: menstrual irregularities, amenorrhea, weight gain, nausea and vomiting. These effects can be adequately managed by a trained service provider. DMPA will be initially introduced by the Department of Health in 10 pilot areas. IMCH will soon introduce the method in our clinics once the supplies are available and the clinic staff are prepared in the service provision of DMPA.
 ...
PMID:PFPP re-introduces DMPA. 1231 88